Mereo Biopharma
Financials
Estimates*
GBP | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | - | 36.5m | - | 7.6m | 11.3m | 12.4m | 31.9m |
% growth | - | - | - | - | 49 % | 10 % | 157 % |
EBITDA | (37.5m) | (20.3m) | (42.1m) | (18.1m) | - | - | - |
% EBITDA margin | - | (56 %) | - | (240 %) | - | - | - |
Profit | (164m) | 12.7m | (34.2m) | (22.3m) | (34.5m) | (28.1m) | (31.2m) |
% profit margin | - | 35 % | - | (295 %) | (305 %) | (227 %) | (98 %) |
EV / revenue | - | 1.4x | - | 28.0x | 39.8x | 42.0x | 16.5x |
EV / EBITDA | -4.6x | -2.5x | -0.7x | -11.7x | - | - | - |
R&D budget | 15.9m | 23.6m | 25.0m | 13.2m | - | - | - |
R&D % of revenue | - | 65 % | - | 174 % | - | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | €14.9m Valuation: €187m -11.8x EV/LTM EBITDA | IPO | |
£20.0m | Post IPO Equity | ||
* | N/A | Post IPO Equity | |
$70.0m | Post IPO Equity | ||
* | $50.0m | Post IPO Equity | |
Total Funding | €108m |
Related Content
Recent News about Mereo Biopharma
EditMereo BioPharma is a biopharmaceutical company focused on developing innovative therapies for patients suffering from rare diseases. Operating in the healthcare and biotechnology market, Mereo BioPharma targets unmet medical needs by advancing a robust portfolio of clinical-stage products. The company's business model revolves around the research, development, and commercialization of novel treatments, primarily through strategic partnerships and collaborations with other pharmaceutical entities. Revenue is generated through licensing agreements, milestone payments, and eventual product sales. Mereo BioPharma serves a niche market of patients with rare and orphan diseases, aiming to provide better treatment options and improve their quality of life. The company is committed to scientific excellence and regulatory compliance, ensuring that its therapies meet the highest standards of safety and efficacy.
Keywords: biopharmaceutical, rare diseases, innovative therapies, clinical-stage products, healthcare, biotechnology, strategic partnerships, licensing agreements, orphan diseases, patient care.